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Background: Mass drug administration (MDA) with azithromycin, carried out for the control of blinding trachoma,
has been linked to reduced mortality in children. While the mechanism behind this reduction is unclear, it may be
due, in part, to improved nutritional status via a potential reduction in the community burden of infectious disease.
To determine whether MDA with azithromycin improves anthropometric indices at the community level, we
measured the heights and weights of children aged 1 to 4 years in communities where one (single MDA arm) or
three annual rounds (annual MDA arm) of azithromycin had been distributed.
Methods: Data collection took place three years after treatment in the single MDA arm and one year after the final
round of treatment in the annual MDA arm. Mean height-for-age, weight-for-age and weight-for-height z scores
were compared between treatment arms.
Results: No significant differences in mean height-for-age, weight-for-age or weight-for-height z scores were found
between the annual MDA and single MDA arms, nor was there a significant reduction in prevalence of stunting,
wasting or underweight between arms.
Conclusions: Our data do not provide evidence that community MDA with azithromycin improved anthropometric
outcomes of children in The Gambia. This may suggest reductions in mortality associated with azithromycin MDA
are due to a mechanism other than improved nutritional status.
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Targeted disease control interventions often have broader
effects on child nutrition and mortality. For example, vac-
cination with measles and Bacille Calmette Guerin (BCG)
vaccines are reported to be associated with reductions in
mortality that cannot be explained solely by the preven-
tion of measles and tuberculosis respectively [1,2]. Reduc-
tions in child mortality have also been associated with
mass drug administration (MDA) with vitamin A, given* Correspondence: Sarah.Burr@lshtm.ac.uk
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unless otherwise stated.for the prevention of childhood blindness [3]. Other bene-
fits of targeted interventions include improved growth and
cognitive function and reductions in intestinal permeabil-
ity associated with MDA with albendazole given for the
treatment of helminth infection [4-6].
MDA with the broad-spectrum antibiotic azithromycin
is a corner-stone of the World Health Organization-
recommended strategy for control of ocular Chlamydia
trachomatis infection, the etiological agent of blinding
trachoma [7,8]. Current WHO guidelines recommend
three annual rounds of MDA with azithromycin in dis-
tricts where the prevalence of follicular trachoma (TF) is
≥10% in children aged 1 to 9 years, with treatment
coverage of at least 80% [9]. Recommended treatment at. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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given at 20 mg/kg to a maximum of 1 g. In Ethiopia,
overall mortality among 1–9 year olds has reportedly been
reduced by 49% in communities receiving intermittent
MDA with azithromycin for trachoma control [10,11].
The publication of these findings has since lead to a call to
further investigate the impact of such MDA on broader
child health measures including anthropometry [12].
While the mechanism underlying the remarkable re-
duction in mortality reported in Ethiopia is not yet clear,
it may be due, in part, to improved nutritional status
among children receiving azithromycin. A recent sys-
tematic review of trials looking at associations of anti-
biotic use and growth has suggested that antibiotic use
promotes both linear growth and weight gain in children
in low and middle-income countries [13]. Diarrhoeal
disease and lower respiratory tract infection are associ-
ated with growth faltering in many low income countries
[14-17] and evidence suggests that MDA with azithro-
mycin reduces the incidence of both respiratory and
gastrointestinal infections [18-20]. It is therefore plaus-
ible that a reduced burden of infectious disease following
MDA leads to improved growth. Environmental enter-
opathy has also been shown to contribute to growth fal-
tering in several African and Asian countries [21-24].
This condition, thought to be caused by chronic expos-
ure to faecal bacteria, leads to microbial translocation
and chronic immune activation [21,25]. Modulation of
the intestinal microbiota, as a result of azithromycin’s
antibacterial action, or a direct reduction in immune ac-
tivation via the immunomodulatory effects of azithromy-
cin [26] may also have the potential to improve an
individual’s growth.
The Partnership for the Rapid Elimination of Trach-
oma (PRET) trial was designed to measure the cost-
effectiveness of approaches to mass treatment with
azithromycin for the control of trachoma [27-30] and
provided an opportunity to investigate improved nutri-
tional status as a possible mechanism for the impact on
mortality attributed to azithromycin. To this end, we
carried out an ancillary study to collect height and
weight measurements of children in the PRET trial com-
munities in The Gambia, West Africa. The aims were to
compare anthropometric indices of children, aged 1–4
years, in communities randomized to receive three annual
rounds of mass azithromycin treatment (annual MDA
arm) to those of children in communities where a single




This study was ancillary to the PRET trial and was ap-
proved by The Gambia Government/Medical ResearchCouncil Unit, The Gambia Joint Ethics Committee. In-
formed, written consent was obtained from each
child’s guardian at the time of examination. The con-
sent form was also signed by an independent witness.
Study design
The PRET study (ClinicalTrials.gov NCT00792922) was
a cluster randomized trial to evaluate coverage and fre-
quency of mass treatment with azithromycin on the
prevalence of active trachoma and ocular C. trachomatis
infection. A detailed description of the trial design has
previously been published [27]. Briefly, clusters, or enu-
merations areas (EAs, population 600–800 individuals),
were randomly sampled from four districts in The
Gambia, West Africa (12 EAs per district). Twenty-four
EAs received three annual rounds of MDA with azithro-
mycin as per current WHO recommendations (annual
MDA arm: MDA at baseline, year one and year two) and
24 EAs received a single round of MDA at baseline (sin-
gle MDA arm). The 48 EAs were further randomized in
a 2 × 2 factorial design to receive standard treatment
coverage (one day visit by treatment team) versus en-
hanced coverage (two visits to each EA). Randomization
of EAs was stratified by district (six EAs per district allo-
cated to either three mass treatments or one).
The PRET trial sample size, 100 children in each of
48 EAs, was estimated in order to power analyses of
trachoma outcomes, which were the prevalence of fol-
licular trachoma (TF) and C. trachomatis infection in
children aged 0–5 year at the three years follow-up
survey; no additional power calculations were per-
formed. Anthropometry measures at the three years
follow-up survey were specified as secondary out-
comes of the trial in April 2011, two months ahead of
the three years follow-up survey. Of the children aged
0–5 years randomly selected for measurement of
trachoma outcomes at the three years follow-up, those
aged 1–4 years were eligible to participate in the an-
thropometry sub-study.
Intervention
The intervention was MDA with a single, oral dose of
azithromycin given at 20 mg/kg body weight, up to 1 g.
Height was used as a proxy for weight [31]. Pregnant
women and infants under the age of 6 months were in-
stead offered tetracycline eye ointment for daily use for
up to 6 weeks. Treatment was distributed to all 48 EAs
at baseline (July-August 2008) and to those 24 EAs
assigned to the annual MDA arm at the one and two
years follow-up. Treatment was distributed by the Gam-
bia’s National Eye Health Programme as previously de-
scribed [29]. Coverage was calculated as the proportion
of residents present at the time of treatment who were
treated.
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Data collection for this ancillary study took place during
the three years follow-up survey of the PRET trial and
was conducted in May and June 2011, corresponding to
three years after treatment in the single MDA arm and
one year after the final round of treatment in the annual
MDA arm (Figure 1). The PRET trial census data, which
was updated every six months and included information
on child name, age, sex and parents, was used to select
children for measurement of trachoma outcomes and
to provide the basis for data on coverage of mass
treatment.
Because data collection took place one year after the
final round of azithromycin treatment in the annual
MDA arm, children under one year of age in this arm
would not have received treatment. We therefore fo-
cused our study on children aged 1–4 years; height and
weight measurements were collected from those chil-
dren, aged 1 to 4 years, who were selected for measure-
ment of trachoma outcomes by the PRET trial. Eligible
children were: resident in the EA, did not have a condi-
tion precluding ocular examination and had a guardian
willing to provide consent. Weight was measured usingFigure 1 Study flow.Seca electronic scales (Seca gmbh & co. kg., Hamburg,
Germany) to within 0.1 kg. Children who were unable to
stand on the scales unaided were held by a parent or
guardian using the tare function to subtract the weight
of the adult. Height was measured with a Seca length
board (for those children unable to stand unaided) or a
Seca Leicester height measure (Seca gmbh & co. kg.,
Hamburg, Germany) to within 0.1 cm. Individuals taking
height and weight measurements participated in stan-
dardized training, conducted by a research clinician,
prior to data collection and were blind to the treatment
arm of each community. Community ophthalmic nurses
and medical doctors treated incidental medical condi-
tions in the field. All visibly malnourished children were
referred to the local health centre for treatment.
Statistical methods
Data were double entered into bespoke databases cre-
ated in Microsoft Access. Analyses were performed
using Stata, version 12 (StataCorp LP, College Station,
Tx, USA).
Community and household attributes at baseline were
summarized by arm by calculating mean summary
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the mean of cluster level summary measures for each
arm. Characteristics of children included in the an-
thropometric study at the three years follow-up were
summarized as the overall number and percentage of
children with each characteristic by study arm.
Height-for-age (HAZ), weight-for-age (WAZ) and
weight-for-height (WHZ) z scores were calculated for chil-
dren aged 1–4 years using user-written WHO programs
for Stata software (http://www.who.int/childgrowth/en/).
Children with a HAZ, WAZ or WHZ <−2 were classified
as stunted, underweight or wasted, respectively [32].
Continuous z score outcome measures were summa-
rized as the overall mean and standard deviation (SD) by
arm. The prevalence of wasting, stunting and under-
weight was summarized using the overall number and
percent of children with each outcome by arm. Only
children aged 1–4 years for whom date of birth data
were available were included in the analyses.
Comparisons were made between anthropometric out-
comes of children residing in the annual MDA arm and
those residing in the single MDA arm to determine
whether repeated treatment was associated with im-
proved growth. The primary analysis on this open
cohort was by intention-to-treat (ITT). A secondary ITT
analysis was conducted in a nested, closed cohort of
children enrolled in the PRET trial at baseline, who
were, in theory, eligible for all three repeated treatments
(dependent on allocation of their community). It was
hypothesised that if there were a beneficial impact of re-
peated annual MDA on anthropometric outcomes, this
secondary analysis would show an emphasised effect.
For each analysis, the same approach was taken; each of
the six outcomes (WAZ, HAZ, WHZ and prevalence of
wasting, stunting and underweight) was compared by
arm (annual MDA versus single MDA) using random
effects linear regression to account for between-community
and between-household variation as appropriate. All chil-
dren aged 1–4 years with available data were included.
Adjustments were made in all models a priori for latrine
access (yes versus no), time to water (<15 minutes versus
≥15 minutes) and district. In order to explore the hypoth-
esis that severely malnourished children would benefit
more from treatment, the distribution of z scores by arm
was formally tested using a Kolmogorov-Smirnov test.
Results and discussion
Study profile
The PRET trial profile is shown in Figure 1. All 48 EAs
received mass treatment at baseline (July to August
2008); treatment coverage in 1–4 year olds ranged from
67.4 to 98.9% at the EA level in both arms. Two further
rounds of mass treatment were carried out at years one
(July to August 2009; EA coverage 67.9 to 100%) andtwo (July to August 2010; EA coverage 65.1 to 98.9%) in
those 24 communities randomized to the annual MDA
arm. Anthropometric indices were measured in all 48
EAs one year following the final round of MDA (May to
June 2011) to explore the hypothesis that better indices
would be seen in children residing in EAs that received
three rounds of MDA versus EAs that had received a
single round.
Community and household attributes at baseline, in-
cluding access to water, access to latrines and level
of household-head education, were balanced by arm
(Table 1). Three years post-baseline, these attributes
were similar to baseline and by arm (data not shown).
A total of 4,816 children aged 0 to 5 years were se-
lected for measurement of trachoma outcomes at the
three years follow-up survey of the PRET trial (Table 1).
Of these, 3423 children aged 1–4 years were eligible for
the anthropometric analysis and within this group, 2886
children (approximately 85% overall and by arm) had
data available for height, weight and date of birth
(Figure 1, Table 1). Children excluded due to missing
data did not differ systematically from the remaining
children and data were therefore assumed to be missing
at random. Final analyses included 1431 children in the
annual MDA arm and 1455 children from the single
MDA arm.
Child level attributes three years post-baseline were
balanced by arm (Table 1) with respect to distribution of
children by age in years, sex and district of residence.
Comparisons of three annual rounds of MDA versus a
single round
A comparison of mean z scores of children residing in
EAs randomized to three rounds of MDA versus those
residing in EAs where a single round of MDA was carried
out revealed no significant differences; the mean z scores
were approximately −1.3 (HAZ), −1.1 (WAZ) and −0.6
(WHZ) in both arms (Table 2). In agreement with these
results, no statistically significant decreases in the preva-
lence of stunting (25% in each arm), underweight (17-18%
per arm) and wasting (8% in each arm) were noted for the
annual MDA versus single MDA arms (Table 2).
By approximately two years of age, growth faltering in
Gambian children slows, consistent with global trends
[33]. One may therefore expect younger children to
benefit more from azithromycin treatment than older
children. However, our data do not show any evidence
of interaction between arm and age group for any of the
z score outcomes (data not shown).
We also examined potential shifts in the distribution
of z scores, hypothesising that severely malnourished
children would benefit more from treatment than other
children. However, analyses found no distributional
change for any of HAZ, WAZ or WHZ scores between
Table 1 Characteristics of study population
Annual MDA Single MDA
Baseline census:
Number of clusters (EA) randomized 24 24
EA population size (all ages), mean (SD)* 705 (239.3) 696 (184.5)
EA population size (1–4 years), mean (SD)* 98 (43.4) 97 (28.5)
Household head years of education, mean (SD)* 0.61 (0.79) 0.51 (0.66)
Household water source >15 minutes away, mean (SD)* 12.0 (14.7) 12.6 (20.2)
Household latrine access, mean (SD)* 90.0 (12.4) 92.0 (9.14)
Year three follow-up:
Number of clusters 24 24
Total number of children aged 0 to 5 years randomly sampled and examined for trachoma outcomes 2442 2374
Number of children aged 1–4 years examined for trachoma outcomes 1727 1696
Number of children aged 1–4 years examined for trachoma outcomes and with anthropological measures 1431 1455
District Foni Bintang 295 (20.6) 357 (24.5)
Foni Kansala 288 (20.1) 327 (22.5)
Lower Baddibu 443 (31.0) 365 (25.1)
Central Baddibu 405 (28.3) 406 (27.9)
Age (years) 1 386 (27.0) 354 (24.3)
2 369 (25.8) 408 (28.0)
3 362 (25.3) 347 (23.9)
4 314 (21.9) 346 (23.8)
Sex Male 741 (51.8) 765 (52.6)
Female 690 (48.2) 690 (47.4)
Active trachoma No 1388 (97.0) 1408 (96.8)
Yes 43 (3.0) 47 (3.2)
*data summary measures are mean (SD) of cluster proportions or means by arm.
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of distributions: WHZ, p = 0.470; HAZ, p = 0.228;
WAZ, p = 0.217).
As the majority of children in the single MDA arm
would not have received azithromycin treatment
(treatment took place three years prior to data collec-
tion) and as children less than 3 years of age in theTable 2 Comparison of outcome measures in all children aged
Outcome Annual MDA N = 1431 Singl
WHZ, mean (SD) −0.60 (1.01) −0.60
HAZ, mean (SD) −1.28 (1.13) −1.35
WAZ, mean (SD) −1.11 (0.96) −1.15
Wasted, n (%) 114 (8.0) 120 (8
Stunted, n (%) 343 (24.0) 371 (2
Underweight, n (%) 242 (16.9) 264 (1
OR = odds ratio, CI = confidence interval.
*adjusted for between-household variation, between-EA variation, latrine access, tim
adjusted models with and without trial arm (annual MDA versus single MDA).
† adjusted for between-household variation and between-cluster variation as appro
from likelihood ratio tests comparing adjusted models with and without arm.annual MDA arm would have received a varying num-
ber of treatment doses (one or two), we also per-
formed an analysis restricted to those children, in
both arms, who were present at the baseline census of
the PRET trial. ITT analyses of this closed cohort
showed no difference between arms for any of the six
measures (Table 3).1 to 4 years in annual MDA versus single MDA trial arms
e MDA N = 1455 Adjusted* coefficient (95% CI), p-value
(1.06) −0.02 (−0.10 to 0.06), 0.651
(1.21) −0.07 (−0.19 to 0.05), 0.257
(1.00) −0.05 (−0.14 to 0.04), 0.264
Adjusted† OR (95% CI), p-value
.3) 1.07 (0.81 to 1.40), 0.642
5.5) 1.12 (0.90 to 1.41), 0.303
8.1) 1.10 (0.89 to 1.37), 0.380
e to water and district. P-values are from likelihood ratio tests comparing
priate and a priori for latrine access, time to water and district. P-values are
Table 3 Comparison of outcome measures in children enrolled in the PRET trial at baseline, in annual MDA versus
single MDA trial arms (aged 3 to 4 years)
Outcome Annual MDA N =569 Single MDA N =577 Adjusted* coefficient (95% CI), p-value
WHZ, mean (SD) −0.69 (0.92) −0.67 (0.94) 0.02 (−0.09 to 0.13), 0.756
HAZ, mean (SD) −1.15 (1.01) −1.16 (1.04) −0.01 (−0.16 to 0.14), 0.885
WAZ, mean (SD) −1.13 (0.88) −1.13 (0.87) 0.01 (−0.10 to 0.12), 0.859
Adjusted† OR (95% CI), p-value
Wasted, n (%) 40 (7.0) 42 (7.3) 1.06 (0.68 to 1.67), 0.796
Stunted, n (%) 107 (18.8) 107 (18.5) 0.98 (0.72 to 1.35), 0.912
Underweight, n (%) 90 (15.8) 90 (15.6) 0.96 (0.70 to 1.32), 0.804
OR = odds ratio, CI = confidence interval.
* adjusted for latrine access, time to water, and district. P-values are from random effects linear regression models.
† adjusted for latrine access, time to water and district. P-values are from comparing random effects logistic regression models with and without trial arm.
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This study has a number of limitations. Due to the de-
sign of the PRET trial, there were no untreated study
EAs, which would have enabled a comparison of one
and three rounds of MDA to no treatment. This would
have been of interest particularly as the greatest de-
creases in child mortality reported in the Ethiopian stud-
ies were seen when comparing treated children to
untreated children [10,11]. The length of time since
MDA differs in each study arm; the cross-sectional sur-
vey took place one or three years after the final round of
MDA in the annual MDA and single MDA arms
respectively. The complexity of the cluster randomised de-
sign and opportunities for multiple treatments (and hence
multiple missed treatments through non-participation)
meant that evaluation of the effect of treatment at the in-
dividual level was not possible. Baseline anthropometric
data from study villages before the commencement of
MDA are also lacking. While close to 1,700 children aged
1–4 years were recruited into each arm of the study, z
scores could not be calculated for approximately 15% of
them, as dates of birth were not available, thereby redu-
cing power. Three individuals took height and weight
measurements and there may have been small systematic
differences between measurers although standardized
training of all workers was undertaken prior to the study
to minimise this effect.
Conclusions
MDA with azithromycin for trachoma control aims to re-
duce the community reservoir of Chlamydia trachomatis
infection thereby interrupting transmission. However, the
broad-spectrum activity of azithromycin may bring add-
itional benefits. For example, MDA with azithromycin
given for trachoma reduces the prevalence of nasopharyn-
geal Streptococcus pneumonia carriage, which in turn has
the potential to reduce the community burden of respira-
tory disease. As infectious disease can drive malnutrition
[34], we hypothesized that children residing in Gambiancommunities were three rounds of MDA were carried out
would have improved anthropometric indices in compari-
son to children residing in communities where a single
round of MDA was given, via a potential reduction in
community burden of infectious disease.
Although azithromycin MDA has been linked with re-
ductions in morbidity and mortality in other settings
and in spite of the PRET trial having achieved high treat-
ment coverage [35], our study did not find evidence that
three annual rounds of MDA improved anthropometric
indices compared to a single round. While the study de-
sign and sample size may have limited the ability to de-
tect a difference, MDA given at yearly intervals may also
not be sufficient to impart lasting improvements on
growth. The PRET trial in Niger has compared an-
thropometric indices of children in communities ran-
domized to annual versus biannual treatment thereby
comparing a single dose with two doses given at 6-
month intervals [36]. In that study, small improvements
for all z scores, including mid-upper arm circumference,
were noted in communities randomized to the biannual
treatment arm although they were not statistically sig-
nificant [36]. This does not provide evidence that MDA
given biannually has a long-term impact on growth. The
reported reductions in incidence of diarrhoeal and re-
spiratory disease following MDA have been shown to
last approximately three months, after which time, inci-
dence rates are similar to that seen in untreated villages
[19,20]. To have a sustained impact, MDA may need to
be given at more frequent intervals however frequent
treatment has been associated with an increase in the
prevalence of carriage of macrolide resistant bacteria
in the community [37] and, as such, requires careful
monitoring.
It may also be that the mechanism by which azithro-
mycin acts (i.e. antibacterial) is not sufficient to drive
significant improvements in anthropometric indicies
in the Gambian setting. In The Gambia, diarrhoeal
disease has been associated with both height and
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shown that much of the burden of diarrhoeal disease
in rural Gambia today is attributable to viral and
protozoan infections (primarily rotavirus and Crypto-
sporidium), which cannot be treated with azithromy-
cin [14]. Although data are limited, respiratory disease
in The Gambia has been associated with weight falter-
ing [15,38]. However, vaccine coverage to protect
against Streptococcus pneumoniae and Haemophilus
influenzae serotype B is high in the country [39] and
data suggest the greater burden of acute lower respira-
tory disease in young Gambian children is due to viral
(RSV and influenza) rather than bacterial infections
[40], which again are not susceptible to azithromycin
treatment.
Our findings do not indicate MDA with azithromycin
for trachoma control has improved anthropometric indi-
ces of Gambian children. Furthermore, data available at
present do not suggest improved nutritional status as a
mechanism behind the reduction in child mortality at-
tributed to intermittent MDA with azithromycin.
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